BCM
GILD icon

BlueCrest Capital Management’s Gilead Sciences GILD Stock Holding History

BlueCrest Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,900
Closed -$964K – 238
2023
Q4 		$964K Hold
11,900
– – 0.04% 173
2023
Q3 		$892K Buy
+11,900
New +$915K 0.04% 186

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlueCrest Capital Management's GILD Position: Q3 2025 in Review

BlueCrest Capital Management sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 13,553 shares — an estimated $1.5M sold.

BlueCrest Capital Management first reported a position in GILD in Q3 2014 and held it in 8 quarters. The position peaked at $2.28M in Q2 2016. 2,027 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • BlueCrest Capital Management reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • BlueCrest Capital Management sold 13,553 Gilead Sciences shares in Q3 2025, an estimated $1.5M.
  • BlueCrest Capital Management first reported a position in Gilead Sciences in Q3 2014 and held it in 8 quarters.
  • BlueCrest Capital Management's Gilead Sciences position peaked at $2.28M in Q2 2016.
  • 2,027 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on BlueCrest Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.